How many syringe units is an AOD-9604 dose?

It depends on your water volume, which is why a fixed chart cannot answer it for every reader. Enter your vial size and water volume in the calculator for the unit mark, or read it off the reconstitution chart below if your combination is on it.

How much bacteriostatic water for an AOD-9604 vial?

Enough that the mark is readable. A microgram dose out of a milligram vial lands at a small unit mark on a concentrated mix, where a small misread is a large proportional error. More water spreads the same dose across more units. Change the water volume in the calculator and the mark and the whole chart move together.

Does AOD-9604 have to be taken fasted?

The engine catalog specifies morning administration on an empty stomach and carries a note saying so, quoted verbatim in the administration section on this page. That is a scheduling constraint rather than a preference, and it is why the timing row matters as much as the dose row.

What does the experience level input change?

It selects a different row in the engine dose table, changing the opening dose, the standard dose, the upper dose and the ceiling. It is the same experience banding the protocol engine uses to set a dose envelope, not a cosmetic filter.

Why do I see a lower maximum quoted elsewhere?

Because two Klarovel data sources carry different ceilings for it and the page prints both. The engine dose table permits an experienced user more than the older research row does, and the engine dose table is the one that binds in production: the dose guard reads its ceilings from there and falls back to the research row only where no dose row exists.

Is AOD-9604 the same as growth hormone?

No. It is a fragment of one end of the molecule, and the reason it was made is that the fragment appeared to carry the fat-metabolism activity without the rest. Whether that separation holds in humans at the doses people use is exactly the question the missing efficacy publication would have answered. The reference list below is what does exist.

Is AOD-9604 banned in drug-tested sport?

Yes. The World Anti-Doping Agency lists growth hormone fragments in section S2 of the prohibited list and names AOD-9604 by name, prohibited at all times, in and out of competition. If you compete under anti-doping rules, check the current list directly rather than relying on any third party.

When is AOD-9604 not appropriate?

The engine's contraindication matrix carries no rule that names this compound or its category, and the conditions section on this page says so rather than filling the space. That is a statement about what the matrix holds, not a statement that nothing here is worth raising with a clinician. The age and kidney or liver impairment rules apply across the whole catalog regardless, and the missing human efficacy publication described above is its own reason for caution.

Where do the numbers on this page come from?

The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.

Is this calculator free?

Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.

Does Klarovel sell this peptide?

No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.

Is this medical advice?

No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

AOD-9604 dosage calculator

AOD-9604 is dosed in micrograms from a milligram vial and taken fasted in the morning, so the ratio between vial and dose is large and the syringe mark is small. Enter your vial size, water volume and experience level for the exact mark.

Below the calculator: a full reconstitution chart, the dose envelope per experience level, the cycle length, a supplies plan, the health conditions that change the answer, and the references. Every dose figure is read from the Klarovel engine's dose table, never typed into the page.

How many milligrams are in your AOD-9604 vial?

How much bacteriostatic water are you adding?

Syringe size

Experience with injectable peptides

Selects the dose row the engine would use, which changes the target, the upper bound and the ceiling together.

Body weight

The engine catalog does not flag AOD-9604 weight sensitive, and the dose calculator applies no generic weight scaling, so this does not change the target. Inventing a per-kilogram rule would be worse than leaving it alone.

Age 65 or over

Standard dose at the beginner level

6.0 units

300 mcg

Concentration: 5 mg/ml
Injection volume: 0.06 ml
Doses per vial: 33

Frequency: once daily. Timing: Morning, fasted. Route: subcutaneous.

Phase by phase, at your mix

The three phases in the order the engine escalates a dose, with the unit mark for each at 10 mg in 2 ml. Change the experience level, weight or age above and the whole table recomputes.

Dose and syringe units per titration phase
Phase	Dose	Draw	Doses per vial
Phase 1, opening dose	250 mcg	5.0 units	40
Phase 2, standard dose	300 mcg	6.0 units	33
Phase 3, upper dose	400 mcg	8.0 units	25
Ceiling, not exceeded	500 mcg	10.0 units	20

Doses read from the beginner row of dose_protocols, the engine's dose table. Unit marks are arithmetic over your vial size and water volume.

AOD-9604 dose envelope by experience level

Every level side by side, unmodified. This is the raw dose table, so the shape of the ramp is visible instead of collapsed into a single recommended number.

Dose envelope per experience level
Experience	Opening	Standard	Upper	Ceiling	Frequency
Never used peptides	250 mcg	250 mcg	300 mcg	500 mcg	once daily
Researched, not used	250 mcg	300 mcg	350 mcg	500 mcg	once daily
Beginner	250 mcg	300 mcg	400 mcg	500 mcg	once daily
Intermediate	300 mcg	400 mcg	500 mcg	1000 mcg	once daily
Experienced	300 mcg	500 mcg	750 mcg	1000 mcg	once daily

Every cell read verbatim from dose_protocols. Where a level repeats the same figure across columns, that is what the table holds: no ramp has been invented to fill the row.

AOD-9604 reconstitution chart

Pre-calculated syringe units for every water volume against the dose figures this compound actually uses, at your selected vial size of 10 mg. A cell reading "n/a" means the draw exceeds a 100-unit syringe at that concentration.

Syringe units per water volume for each sourced dose figure
BAC water	Conc.	Opening250 mcg	Standard300 mcg	Upper400 mcg	Ceiling500 mcg
1 ml	10 mg/ml	2.5	3	4	5
1.5 ml	6.67 mg/ml	3.8	4.5	6	7.5
2 ml	5 mg/ml	5	6	8	10
2.5 ml	4 mg/ml	6.3	7.5	10	12.5
3 ml	3.33 mg/ml	7.5	9	12	15
4 ml	2.5 mg/ml	10	12	16	20
5 ml	2 mg/ml	12.5	15	20	25

Column doses are the beginner row's opening, standard, upper and ceiling figures from dose_protocols. Unit marks are arithmetic.

Supplies for one cycle

One on-cycle runs 12 weeks followed by 6 weeks off, from the engine catalog. Multiplied out at the standard dose and your mix, that is what the cycle costs in consumables.

Bacteriostatic water bottle size

Supplies for one on-cycle
Cycle length	12 weeks on, 6 weeks off
Administrations per week	7
Total administrations	84
Vials of 10 mg	3
Insulin syringes	84 (30-unit holds the draw)
Bacteriostatic water	6 ml, 1 bottle of 10 ml

Cycle length, loading phase and taper from PEPTIDE_CATALOG. Administrations per week derived from the frequency string on the dose row. Counts are arithmetic.

Save your reconstitution. Get the protocol it belongs in.

Free founding-member access while spots last. We'll send your reconstitution + a link to claim your slot.

About AOD-9604

AOD-9604 is a synthetic fragment of the C-terminal region of human growth hormone, the stretch the early papers number 177 to 191. Its interest is a separation: work going back to the 1970s and 1980s reported that this end of the molecule carries fat-metabolism activity while the intact hormone's effects on glucose and growth sit elsewhere. Rodent studies published in 2000 and 2001 reported increased fat oxidation and weight loss on chronic treatment without the growth-promoting action of the whole hormone.

The human record is thinner than the compound's reputation suggests, and it is worth being specific about how. The published pharmacology is largely animal work plus a 2004 development summary in Current Opinion in Investigational Drugs. The obesity efficacy trial that the compound is usually described by is not registered on ClinicalTrials.gov and has no primary-source publication we could locate. Saying that plainly is more useful than repeating a result nobody can read.

Two regulatory facts a reader is likely to want. AOD-9604 is not approved by the FDA. It is prohibited at all times in drug-tested sport: the World Anti-Doping Agency lists growth hormone fragments under section S2 and names AOD-9604 explicitly. Neither statement is a verdict on the compound; both are things a search result should tell you rather than leave you to find out later.

Administration and cycling

Administration and cycling reference
Route	subcutaneous
Timing	Morning, fasted
Catalog frequency	once daily
Cycle	12 weeks on, 6 weeks off
Taper before the off period	Not specified
Loading phase	None
Weight sensitive	No

Catalog note: Inject 300 mcg subcutaneously in the morning on an empty stomach. Fat-burning fragment of growth hormone without GH elevation.

Every row above is read from PEPTIDE_CATALOG, the engine catalog, and the note is quoted verbatim rather than paraphrased.

Two ceilings, and which one binds

Klarovel holds two upper bounds for AOD-9604 in two different places, and they do not agree. The engine dose table puts the highest ceiling at 1000 mcg across the experience levels. The older research row carries 600 mcg.

The engine dose table is the one that binds. The dose guard that caps generated protocols reads its ceilings from that table and falls back to the research row only where no dose row exists, because a guard that fights the engine trims legitimately curated doses and trains everyone to ignore its warnings.

Both figures are printed here rather than one, so a reader who finds the lower number elsewhere can see that both exist and which one the software actually uses.

When this would not be recommended for you

A public page cannot know your health data, so it cannot tell you whether a compound is appropriate. What it can do is list the conditions the engine's contraindication matrix associates with this compound, and what the engine does about each. In a generated protocol these resolve automatically and the reason is shown alongside the exclusion.

The engine's contraindication matrix carries no rule that names this compound or its category. That is what the matrix holds, not a statement that nothing is worth discussing with a clinician. Age and kidney or liver impairment apply across the catalog regardless.

Questions

How many syringe units is an AOD-9604 dose?: It depends on your water volume, which is why a fixed chart cannot answer it for every reader. Enter your vial size and water volume in the calculator for the unit mark, or read it off the reconstitution chart below if your combination is on it.
How much bacteriostatic water for an AOD-9604 vial?: Enough that the mark is readable. A microgram dose out of a milligram vial lands at a small unit mark on a concentrated mix, where a small misread is a large proportional error. More water spreads the same dose across more units. Change the water volume in the calculator and the mark and the whole chart move together.
Does AOD-9604 have to be taken fasted?: The engine catalog specifies morning administration on an empty stomach and carries a note saying so, quoted verbatim in the administration section on this page. That is a scheduling constraint rather than a preference, and it is why the timing row matters as much as the dose row.
What does the experience level input change?: It selects a different row in the engine dose table, changing the opening dose, the standard dose, the upper dose and the ceiling. It is the same experience banding the protocol engine uses to set a dose envelope, not a cosmetic filter.
Why do I see a lower maximum quoted elsewhere?: Because two Klarovel data sources carry different ceilings for it and the page prints both. The engine dose table permits an experienced user more than the older research row does, and the engine dose table is the one that binds in production: the dose guard reads its ceilings from there and falls back to the research row only where no dose row exists.
Is AOD-9604 the same as growth hormone?: No. It is a fragment of one end of the molecule, and the reason it was made is that the fragment appeared to carry the fat-metabolism activity without the rest. Whether that separation holds in humans at the doses people use is exactly the question the missing efficacy publication would have answered. The reference list below is what does exist.
Is AOD-9604 banned in drug-tested sport?: Yes. The World Anti-Doping Agency lists growth hormone fragments in section S2 of the prohibited list and names AOD-9604 by name, prohibited at all times, in and out of competition. If you compete under anti-doping rules, check the current list directly rather than relying on any third party.
When is AOD-9604 not appropriate?: The engine's contraindication matrix carries no rule that names this compound or its category, and the conditions section on this page says so rather than filling the space. That is a statement about what the matrix holds, not a statement that nothing here is worth raising with a clinician. The age and kidney or liver impairment rules apply across the whole catalog regardless, and the missing human efficacy publication described above is its own reason for caution.
Where do the numbers on this page come from?: The dose table, the ceilings and the frequency come from the Klarovel engine's own dose table, the same rows the protocol generator doses from. Route, timing, cycling and weight sensitivity come from the engine catalog. Nothing on this page is a number someone typed into an article, which is the failure mode most dosing pages share.
Is this calculator free?: Yes. No account, no paywall, no usage limit. The protocol engine behind it is a separate product, but the calculator is open.
Does Klarovel sell this peptide?: No. Klarovel is the protocol layer: a questionnaire, a deterministic rules engine and a generated protocol. Any product is fulfilled by partner suppliers, not by Klarovel.
Is this medical advice?: No. It is arithmetic over published dose data, presented as a reference. It is not a prescription and not a recommendation to use any compound. Discuss peptide use with a qualified clinician.

Other peptide calculators

References

These papers cover AOD-9604 and the growth hormone C-terminal fragment it derives from: the original antilipogenic and glucose-transport work from the 1970s to 1990s, the rodent fat-oxidation studies, the oral administration study, the 2004 clinical development summary, an intra-articular osteoarthritis model, and the anti-doping analytical literature. They are not the source of the dose figures on this page.

The dose figures on this page are not sourced from these papers. They are read from the Klarovel engine's own dose table, which is cited inline wherever a number appears. These references cover mechanism, pharmacology and clinical context.

12 references, every identifier resolved against NCBI on 2026-08-03. Per peptide, a relevance-sorted esearch was run and every returned id was resolved through esummary. Any id esummary could not resolve was dropped, and any record carrying the 'Retracted Publication' pubtype was dropped. Titles, journals, years and first authors below are the values esummary returned, not authored text. One retracted record was dropped: PMID 37696839 (thymosin beta 4 query). Regenerated 2026-08-03 for cjc1295_no_dac, ipamorelin, pt141, retatrutide, aod9604 and sermorelin using the same esearch + esummary procedure; no record was added whose esummary payload lacked a title, journal or first author.

1.Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord 2001. PMID 11673763
2.Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology 2001. PMID 11713213
3.Heffernan MA et al. Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism. Am J Physiol Endocrinol Metab 2000. PMID 10950816
4.Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res 2000. PMID 11146367
5.Wu Z et al. Antilipogenic action of synthetic C-terminal sequence 177-191 of human growth hormone. Biochem Mol Biol Int 1993. PMID 8358331
6.Ng FM et al. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol 1978. PMID 645904
7.Wade JD et al. Effect of C-terminal chain shortening on the insulin-antagonistic activity of human growth hormone 177--191. Acta Endocrinol (Copenh) 1982. PMID 6751009
8.Wilding J et al. AOD-9604 Metabolic. Curr Opin Investig Drugs 2004. PMID 15134286
9.Orlovius AK et al. AOD-9604 does not influence the WADA hGH isoform immunoassay. Drug Test Anal 2013. PMID 24124033
10.Cox HD et al. Detection and in vitro metabolism of AOD9604. Drug Test Anal 2015. PMID 25208511
11.Kwon DR et al. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci 2015. PMID 26275694
12.Dominikowski A et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMID 42395176 PMC13322892

Beyond the arithmetic

Your health data, your protocol.

A calculator converts a dose into syringe units. The Klarovel engine decides the dose: it reads your health data, resolves contraindications, sets the envelope by experience level, removes incompatible pairs and builds the cycling and monitoring schedule. Blood work is optional and sharpens the result. It is never required.